A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy

Chemotherapy Induced Anemia Clinical Trial

Official title:
A Multicenter, Randomized, Open-label Study of AND017 for the Treatment of Cancer-Related Anemia Patients Receiving Chemotherapy

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to determine the safety and efficacy of AND017 after 6 weeks of treatment in patients with cancer-related anemia who are receiving chemotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06075030
Study type	Interventional
Source	Kind Pharmaceuticals LLC
Contact	Yusha Zhu, MD, PhD
Phone	6467252552
Email	yushazhu@kindpharmaceutical.com
Status	Not yet recruiting
Phase	Phase 2
Start date	December 2024
Completion date	May 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05301517` - A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies	Phase 3
Terminated	`NCT00931606` - Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)	Phase 2
Completed	`NCT00272662` - Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy	Phase 2
Completed	`NCT00144495` - A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy	Phase 3
Completed	`NCT00144482` - A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy	Phase 3
Completed	`NCT04076943` - Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia	Phase 2